Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 January 2024 | Story Leonie Bolleurs | Photo Born2shoot
Dr Tommie van Zyl, Prof Philippe Burger and Prof Francis Petersen
At the launch of NovaLogix, a company co-owned by the UFS and ZZ2, were, from the left, Dr Tommie van Zyl, CEO of the ZZ2 Group, and Prof Philippe Burger, Dean of the Faculty of Economic and Management Sciences, and Prof Francis Petersen, Vice-Chancellor and Principal.

The University of the Free State (UFS) recently (17 January 2024) launched NovaLogix in collaboration with ZZ2, a well-known South African fresh produce company.

This new company, co-owned by the university and ZZ2, aims to develop and produce a probiotic used in the production of fresh produce to enhance plant health and growth. Projects include a focus on improved production techniques, product registration, commercialisation, and improved recipes.

Members of the university’s management structures were present at the formal launch of NovaLogix – which took place on the UFS Bloemfontein Campus – including the Vice-Chancellor and Principal, Prof Francis Petersen; the Deputy Vice-Chancellor: Research and Internationalisation, Prof Vasu Reddy; and the Senior Director of the Directorate Research Development, Dr Glen Taylor. The deans of the two faculties that will be mainly involved in this partnership were also present, namely Prof Paul Oberholster, the Dean of the Faculty of Natural and Agricultural Sciences, and Prof Philippe Burger, the Dean of the Faculty of Economic and Management Sciences.

Among the attendees representing ZZ2 were Dr Tommie van Zyl, the Chief Executive Officer of the ZZ2 Group, Piet Prinsloo, Executive Manager at ZZ2, as well as Wiam Haddad, the new CEO of NovaLogix.

Co-creation and more sustainable outcomes

In his welcoming remarks, Prof Petersen stated that this event marks the culmination of a five-year journey that began in 2019 when he, Prof Burger, and Prof Danie Vermeulen, former Dean of the Faculty of Natural and Agricultural Sciences, first visited ZZ2 to initiate closer collaboration and cooperation.

He is of the opinion that the relationship with ZZ2 is ideally suited to assist the university in realising the core values of Vision 130, the university’s strategic intent to reposition the institution as one of the leading universities in South Africa by 2034.

The knowledge, experience, and expertise that ZZ2 brings to the partnership, complement the exciting and impactful research done by the university’s academics across a range of disciplines. - Prof Francis Petersen

Prof Petersen said that the UFS values partnerships with the private sector, and he considers ZZ2 to be a knowledge partner with co-creation as a key component in this collaboration.

“Working together on a challenge makes the solution more sustainable. I believe that innovation and this co-creation approach will generate outcomes that transform the agricultural sector and impart knowledge to the next generation,” he stated.

“The knowledge, experience, and expertise that ZZ2 brings to the partnership complement the exciting and impactful research conducted by the university’s academics across a range of disciplines. I am looking forward to a partnership that will grow from strength to strength,” concluded Prof Petersen.

Breakthrough developments in the pipeline

According to Dr Van Zyl, ZZ2 would like to continue building a future with the university based on a symbiotic relationship. “We want to ensure that our strengths as an organisation are put to good use,” he said, expressing a strong conviction that there will be breakthrough developments with this initiative.

This work will align with ZZ2’s ‘Work with nature’ journey that began more than two decades ago, steering away from conventional, industrial agriculture towards a system that aims to farm in harmony with nature. “It is important that we nurture nature while using her resources,” he said.

He is excited to work with the university, exploring improved techniques and technologies to find more effective ways towards a sustainable future. “Knowledge partners are important in this journey,” he stated.

Building on existing collaborations

In September 2022, the university entered into a collaboration agreement with ZZ2. The partnership between the two entities included the establishment of FreeFarm Innovation, a company that in turn has a holding in NovaLogix and is designed to leverage the strengths, capabilities, skills, and resources of both parties. Part of the operations of FreeFarm Innovation included opportunities for research, commercialisation, and the enhancement of agricultural products. This has come into effect in projects on, for example, business operations, agricultural sustainability, and innovative approaches to growing fruit and vegetables, to name but a few.

News Archive

UFS researcher explores the future cost of cancer
2017-01-10

 Description: 001 Dr Alicia Sherriff Tags: 001 Dr Alicia Sherriff

Dr Alicia Sherriff, Head the Department of Oncology
at the UFS Faculty of Health Sciences, co-authored
an article in the South African Medical Journal.

Photo: Charl Devenish

Cancer is on an exponential rise globally, and the cost of treatment is a growing international problem. South Africa alone is expected to see a 78% increase in cancer cases. Dr Alicia Sheriff, Head of the Department of Oncology, collaborated on and co-authored a research paper for the South African Medical Journal on the future of oncology treatment in the country, along with doctors from various universities across South Africa. The article, titled "The future cost of cancer: interdisciplinary cost management strategy", looks at the prognosis of cancer management in the country.

Cancer is on the rise

There is a visible growth of the cancer disease in the developing world. Rapidly changing lifestyles, uncontrolled urbanisation, pollution, and population ageing are some dynamics that provide a lethal cocktail of infectious and lifestyle risk factors that leave people at a higher risk of developing cancer.

The simultaneous increase in cancer incidence has increased the cost of treatment exponentially. The cost of cancer treatment is multitiered, making the provision of care for cancer patients a high-risk business. A combination of treatment delays, limited resources, differently skilled personnel, high patient volumes and advanced disease stage on presentation all place a bigger burden on the delivery of optimal cancer care outcomes.

Adoption of new strategies

According to the doctors, innovative thinking to embrace technology, combined with a preventive approach, as well as lowering the cost of treatment drugs should be prioritised. So should the commercialisation of new technologies that will diagnose and treat cancer in its early stages. They also encourage interdisciplinary research funding in South Africa as a way to better understand the demographic and molecular dynamics of cancer in the country, along with retaining more oncologists in the public health sector.

Efficient solutions to curb cancer mortality

The doctors assert there is a need to continue to look for more efficient measures to best treat the disease, and hopefully bring about a change in mortality levels in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept